Do Traders Think Fate Therapeutics Inc (FATE) Can Keep Climbing Wednesday?

Fate Therapeutics Inc (FATE) stock has risen 13.19% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Fate Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on FATE!

See Full FATE Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With FATE Stock Today?

Fate Therapeutics Inc (FATE) stock has gained 1.73% while the S&P 500 is lower by -1.04% as of 12:55 PM on Wednesday, Oct 18. FATE has gained $0.04 from the previous closing price of $2.02 on volume of 1,468,314 shares. Over the past year the S&P 500 has risen 17.67% while FATE is lower by -90.23%. FATE lost -$2.17 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Fate Therapeutics Inc click here.

More About Fate Therapeutics Inc

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. Click Here to get the full Stock Report for Fate Therapeutics Inc stock.